CA2538895A1 - Factor ixa specific antibodies displaying factor viiia like activity - Google Patents

Factor ixa specific antibodies displaying factor viiia like activity Download PDF

Info

Publication number
CA2538895A1
CA2538895A1 CA002538895A CA2538895A CA2538895A1 CA 2538895 A1 CA2538895 A1 CA 2538895A1 CA 002538895 A CA002538895 A CA 002538895A CA 2538895 A CA2538895 A CA 2538895A CA 2538895 A1 CA2538895 A1 CA 2538895A1
Authority
CA
Canada
Prior art keywords
antibody
factor
seq
nos
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002538895A
Other languages
English (en)
French (fr)
Inventor
Friedrich Scheiflinger
Randolf Kerschbaumer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34273861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2538895(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2538895A1 publication Critical patent/CA2538895A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002538895A 2003-09-12 2004-09-07 Factor ixa specific antibodies displaying factor viiia like activity Abandoned CA2538895A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/661,366 2003-09-12
US10/661,366 US7297336B2 (en) 2003-09-12 2003-09-12 Factor IXa specific antibodies displaying factor VIIIa like activity
PCT/EP2004/009975 WO2005025615A2 (en) 2003-09-12 2004-09-07 FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY

Publications (1)

Publication Number Publication Date
CA2538895A1 true CA2538895A1 (en) 2005-03-24

Family

ID=34273861

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002538895A Abandoned CA2538895A1 (en) 2003-09-12 2004-09-07 Factor ixa specific antibodies displaying factor viiia like activity

Country Status (9)

Country Link
US (1) US7297336B2 (enExample)
EP (1) EP1660536B1 (enExample)
JP (1) JP4887148B2 (enExample)
AT (1) ATE419277T1 (enExample)
AU (1) AU2004271706B2 (enExample)
CA (1) CA2538895A1 (enExample)
DE (1) DE602004018788D1 (enExample)
ES (1) ES2320665T3 (enExample)
WO (1) WO2005025615A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
PT1876236E (pt) * 2005-04-08 2014-10-22 Chugai Pharmaceutical Co Ltd Anticorpos para substituição da função do factor de coagulação sanguínea viii
EP1760092A1 (en) * 2005-08-26 2007-03-07 Applied Research Systems ARS Holding N.V. System for screening cells for high expression of a protein of interest
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
BR112015006634B1 (pt) * 2012-09-28 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Método e kit para avaliação de reação de coagulação sanguínea
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
CN106456749B (zh) 2014-03-11 2021-03-30 小利兰·斯坦福大学托管委员会 抗SIRPα抗体和双特异性巨噬细胞增强型抗体
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
CR20180554A (es) 2016-04-28 2019-01-10 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos
KR102625416B1 (ko) * 2016-05-16 2024-01-15 다케다 파머수티컬 컴패니 리미티드 항-인자 ix 파두아 항체
US20190185578A1 (en) 2016-07-29 2019-06-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
PL3509637T3 (pl) 2016-09-06 2025-03-10 Chugai Seiyaku Kabushiki Kaisha Sposoby zastosowania dwuswoistego przeciwciała, które rozpoznaje czynnik krzepnięcia IX i/lub aktywowany czynnik krzepnięcia IX oraz czynnik krzepnięcia X i/lub aktywowany czynnik krzepnięcia X
US20190248920A1 (en) * 2016-09-23 2019-08-15 Csl Limited Coagulation factor binding proteins and uses thereof
TN2019000164A1 (en) * 2016-11-23 2020-10-05 Bioverativ Therapeutics Inc Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
EP3577140A1 (en) 2017-02-01 2019-12-11 Novo Nordisk A/S Procoagulant antibodies
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
PE20210005A1 (es) 2017-09-29 2021-01-05 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
AU2019313550B2 (en) 2018-08-01 2024-02-08 Novo Nordisk A/S Improved procoagulant antibodies
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
US10815308B2 (en) 2018-12-21 2020-10-27 Kymab Limited FIXaxFX bispecific antibody with common light chain
US20250376538A1 (en) 2020-01-30 2025-12-11 Novo Nordisk A/S Bispecific factor viii mimetic antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2143125C (en) 1992-08-27 2008-09-23 Koenraad Mertens Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
DK128093D0 (da) 1993-11-12 1993-11-12 Novo Nordisk As Hidtil ukendte forbindelser
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
JP2002510321A (ja) 1997-07-03 2002-04-02 スミスクライン・ビーチャム・コーポレイション 抗−第ＩＸ因子 Ｆａｂフラグメントの結晶構造およびペプチド模倣物デザインのための使用方法
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
EP1383785B1 (en) * 2001-05-03 2011-03-16 Merck Patent GmbH Recombinant tumor specific antibody and use thereof

Also Published As

Publication number Publication date
ES2320665T3 (es) 2009-05-27
JP4887148B2 (ja) 2012-02-29
US20050058640A1 (en) 2005-03-17
DE602004018788D1 (de) 2009-02-12
US7297336B2 (en) 2007-11-20
EP1660536A2 (en) 2006-05-31
AU2004271706B2 (en) 2010-09-02
EP1660536B1 (en) 2008-12-31
AU2004271706A1 (en) 2005-03-24
JP2007504812A (ja) 2007-03-08
WO2005025615A3 (en) 2005-06-02
WO2005025615A2 (en) 2005-03-24
ATE419277T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
CA2538895A1 (en) Factor ixa specific antibodies displaying factor viiia like activity
JP7146871B2 (ja) 血漿カリクレイン結合タンパク質
EP1220923B1 (en) FACTOR IX/FACTOR IXa ACTIVATING ANTIBODIES
JP6900500B2 (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
CN102143979B (zh) 针对组织因子途径抑制剂(tfpi)的单克隆抗体
ES2765418T3 (es) Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
JP2019507107A (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体及びその使用
CN105713092A (zh) 血浆前激肽释放酶结合蛋白
TW201522368A (zh) 抗組織因子路徑抑制劑之前藥抗體
WO2006117910A1 (ja) 抗血小板膜糖蛋白質ⅵモノクローナル抗体
JPH09502708A (ja) Ｉｌ４により伝達される疾患の治療に有用な組み換え型ｉｌ４抗体
BRPI0707848A2 (pt) mÉtodos para selecionar pelo menos uma molÉcula, para produzir uma composiÇço, para incrementar degradaÇço de proteÍna extracelular e / ou eliminaÇço de proteÍna em um indivÍduo, para inibir, pelo menos em parte, efeitos mediados por proteÍna mal-dobrada e e/ou estrutura b cruzada, para prevenÇço pelo menos parcial e/ou tratamento de uma doenÇa, de um distérbio e/ou de uma infecÇço, para remover, pelo parcialmente, proteÍnas mal-dobradas, estruturas b cruzadas e/ou proteÍnas, para determinar se uma proteÍna mal-dobrada, e/ou uma proteÍna e/ou peptÍdeo compreendendo uma estrutura b cruzada estÁ presente em uma soluÇço aquosa, para reduzir e/ou prevenir efeitos secundÁrios indesejados de uma composiÇço farmacÊutica e/ou incrementar a atividade especÍfica por grama de proteÍna, para interferir na coagulaÇço do sangue, para determinar a quantidade de proteÍnas mal-dobradas e/ou estruturas b cruzadas em uma composiÇço, para determinar uma diferenÇa no teor de estrutura b cruzada, para determinar a identidade de uma proteÍna mal-dobrada, de uma estrutura b cruzada ou de uma proteÍna, e para tratar um sujeito que sofre de, ou em risco de sofrer de, uma doenÇa, um distérbio e/ou uma infecÇço, coleÇço de molÉculas de igiv, composiÇço, uso de uma coleÇço de molÉculas igiv e/ou de uma composiÇço, kit diagnàstico, dispositivo de separaÇço, composto, e, uso de um composto
JP2002523081A (ja) ヒト抗−ＩＸ／ＩＸａ因子抗体
TW200407335A (en) Non-neutralizing antibody to inhibit the inactivation of activated protein C
US20140271661A1 (en) Monoclonal antibodies against antithrombin beta
TWI673063B (zh) 抗蛋白ｃ抗體之出血性疾病的治療
BR112018069283B1 (pt) Anticorpos monoclonais contra o sítio ativo de fator xi e usos dos mesmos

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130107